Bi-directional Integration with Oracle Health Sciences InForm Enables Real-time Clinical Trial Data Visibility and Reduces Data Management Costs
Oracle announced the release of the Oracle Health Sciences Data Management Workbench. The tool aims to allow researchers to "integrate, reconcile, and analyze clinical data faster and more accurately," automating the data load, transform and cleanse processes.
The solution integrates with Oracle Life Sciences Data Hub to automatically aggregate, integrate, and recincile the volume of trial data. By increasing data integration and standardizing data formats throughout the study process, Oracle Health Sciences Data Management Workbench also automates the identification and correction of discrepancies in multi-source data that can jeopardize the validity of a study. Oracle Health Sciences Data Management Workbench also integrates with Oracle Health Sciences InForm to enable automated, bi-directional and real-time information flow between the systems.
Read the full release here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.